SUSTech offers unprecedented opportunities for undergraduate and graduate students to work alongside the faculty to explore and tackle both fundamental and practical problems. 

The Global Engagement Office (GEO) is responsible for forming and implementing a coherent strategy to promote the University’s international development and global profile.

The undergraduate admission of SUSTech adopts comprehensive evaluation enrollment mode based on national college entrance examination.The graduate admission of SUSTech currently adopts joint training mode.

The main duties of SUSTCEF is to accept the donations from the domestic and foreign associations, enterprises, trading companies and individuals, and establish the funding projects depending on the demands of the university and the wishes of the donors.

SUSTech Faculty Finder

Home > Faculty > SUSTech Faculty Finder > Zhang Jian


Zhang Jian


School of Medical



Jian Zhang, MD. PhD., is a Professor and Deputy Director of Southern University of Science and Technology (SUStech) Medical School Planning Office. Dr Zhang received his MD degree in Department of Medicine from Tianjin Medical University, Tianjin, China, in 1986, and a PhD. in Pathology from the University of Michigan, Ann Arbor, Michigan, in 2001. After a three-year postdoctoral fellowship at the University of Michigan, Dr. Zhang served as a tenure-track Assistant Professor at the University of Pittsburgh and the University of Michigan, Department of Internal Medicine and the University of Michigan Comprehensive Cancer Center. In 2011, his team returned to China and set up the 1st Center for Translational Medicine in Southwest of China. From 2011-2016, he serves as a professor and founder/director for the Key Laboratory of Longevity and Aging-related Diseases, Ministry of Education, China. In late 2016, he joined the SUStech as the deputy director and professor for medical school planning Office. His research interests have been focused on the study of aging-related diseases incluing aging-associated cancer biology. In particular, he has expertise in tumor microenvironment, chemoresistance and metastasis. He is the author/co-author of over 100 peer-reviewed publications and a reviewer for Department of Defense panel of cancer pathobiology, Cancer Research UK program, and Australia Prostate Cancer Research Program and Key Projects in National Science Foundation and “Changjiang Scholar” China. From 2015-2017, he served as the associate editor for “Medical Oncology”.
1981-1986: Bachelor, Department of clinical medicine, Tianjin medical university
1997-1998: Master, Old Dominion University & East Virginia Medical School, immunology
1998-2001: Doctor, University of Michigan, pathology
1986.8-1995.1 Resident/Attending Doctor, Tianjin third hospital/tianjin institute of geriatrics
1995.1-1996.8 Visiting Scholar, Institute of geriatrics, university of Wisconsin-Madison,  supporting by the fellowship of the World Health Organization
1996.8-1998.8 Visiting Research Scientist, Center for geriatric research at eastern Virginia medical school
1998.8-2004.6 PhD student/Researcher, University of Michigan school of medicine
2004.7-2010.12 Assistant Professor (Tenure track), school of medicine, university of Pittsburgh and university of Michigan
2011.1-2016. 7 Director/Professor, Key laboratory of longevity and geriatric diseases, Ministry of Education, school of translational medicine, Guangxi medical university,
2016.3- Adjunct Professor, university of Pittsburgh, school of medicine
2016.7- Associate Director/Professor, school of medicine, southern university of science and technology
Translational research on discovery of tumor biomarkers and validation of cancer therapeutic targets
Chemoresistance, relapse and tumor metastasis
Aging and cancer
2014-Experts with special government allowance from the state council
2013-National Talents Engineering, young and middle-aged experts with outstanding contributions
2013-International lecturer, Society for Basic Urology Research (SBUR)
2012-Outstanding national scientists and technicians
2011-Bagui Scholars of Guangxi Autonomous Region, counselor to the government of Guangxi Autonomous Region
2007-Mentoring Dr. Yi Lu, Young Investigator Travel Award, ASBMR
2005-Mentoring Dr. Yi Lu, Scholar-in-Training Award, AACR
2003-Scholar-in-Training Award, AACR
2003- Plenary Poster Award of 25th Annual Meeting of American Society for Bone and Mineral Research
2002-Alice L. Jee Memorial Young Investigator Award
2000-Plenary Poster Award of 22nd Annual Meeting of American Society for Bone and Mineral Research
1994- Fellowship Award, World Health Organization (WHO)
1. Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235-1244, 2001.
2. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Antioxidant & Redox Signaling. 3:493-504, 2001.
3. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256-1263, 2002.
4. Zhang J, J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone. Cancer Res. 63:7883-90, 2003
5. Zhang J, Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo. Prostate. 59:360-9, 2004
6. Zhang J, Dai J, Lu Y, Yao Z, O’Brein C, Qi W, Hall D, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. Experimental Gerontology. 39:239-247, 2004
7. Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J*. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 66:1311-8, 2006
8. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J*. Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption. Cancer Res, 67:3646-53, 2007
9. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, and Zhang J*.   CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 101:676-685, 2007
10. Lu Y, Yao Z, and Zhang J*. Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment. Chin J of Biochem and Molecul Biol, 23(3):167-171, 2007
11. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J*. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.   Int J of Cancer. 121:724-733, 2007
12. Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J*. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation. Mol Cancer Therapeutics, 7(10):3203-11, 2008
13. Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, and Zhang J*. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res, 6(4): 546-54, 2008
14. Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, and Zhang J*. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2):161-9, 2009
15. Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, and Zhang J*. MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia, 11(3):228-236, 2009
16. Zhang J, Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1):41-8, 2010
17. Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J Natl Cancer Inst. 102(8):522-8, 2010
18. Zhang J*, Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011
19. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.
20. Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET, Zhang J*, Deng J*,Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. Plos One. 9(6):e100394, 2014
21. Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J*. Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer, 2014, 5; 473-86
22. Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou* , and Zhang J*. Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759-7714.12294
23. Yu Zhu, Chunlin Zou, Zhe Zhang, Chaonan Qian, Xin Yang, Junlin Shi, Yudui Xia,  Zhang J*, Yi Lu*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression. Tumor Biology, 2015, 36(11):8811-8.
24. Sha He, Yi Lu, Xia Liu, Xin Huang, Evan Keller, Chao-Nan Qian*,  Zhang J *; Wnt3a: function and implication in cancer. Chinese Journal of Cancer, 2015, 34(3):50.
25. Lihui Wang, Yanli He, Weijun Liu, Shengbin Bai, Lei Xiao, Jie Zhang, Saravana M. Dhanasekaran, Zhuwen Wang, Shanker Kalyana-Sundaram, O. Alejandro Balbin, Sudhanshu Shukla, Yi Lu, Jules Lin, Rishindra M. Reddy, Philip W. Carrott, Jr., William R. Lynch, Andrew C. Chang, Arul M. Chinnaiyan, David G. Beer*, Zhang J*, Guoan Chen*. Non-coding RNA LINC00535 promotes lung adenocarcinoma progression via the Akt pathway. Oncotarget, 7(10):11487-99,2016.
26. Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lu*, Zhang J*. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016, 49:838-846.
27. Yeguo Yang, Yi Lu, Lihui Wang, Atsushi Mizokami, Evan T. Keller, Zhang J*, Jiejun Fu*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27. Oncology Reports, 2016, 36:559-566.
28. Yang Liu, Yi Chai, Zhang J*, and Junwei Tang*. A function variant at miR-501 alters susceptibility thepatocellular carcinoma in a Chinese han population. Cell Physiol Biochem, 38(6):2500-8, 2016.
29. Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J, Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget, 2016, Oct 18;7(42):68140-68150.
30. Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 2017; 36(1):17.
31. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D*, Deng J*, and Zhang J*. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep. 2017; 7: 41656.
32. Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* and Jian Zhang*. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017; 36:35
33. Yutao Gao, Xia Liu, Ting Li, Luwei Wei, Antai Yang, Yi Lu, Jian Zhang, Li Li, Sumei Wang and Fuqiang Yin. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncology Reports. 2017; DOI: 10.3892/or.2017.5534
34. Jinlu Dai, Yi Lu, Hernan Roca, Jill M. Keller, Jian Zhang, Laurie K. McCauley and Evan T. Keller. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer, 2017; 36:29

© 2015 All Rights Reserved. 粤ICP备14051456号 Address:No 1088,xueyuan Rd., Xili, Nanshan District,Shenzhen,Guangdong,China 518055 Tel:+86-755-8801 0000